SCHEMBL294884

SCHEMBL294884

Ic1cnc2[nH]ccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 9/20 0.55
AXL P30530 3/20 0.55
PIK3CD O00329 1/20 0.53
PIK3CA P42336 1/20 0.53
PIK3CB P42338 1/20 0.53
PIK3CG P48736 1/20 0.53
RIPK1 Q13546 4/20 0.51
NUDT1 P36639 2/20 0.47
KDR P35968 3/20 0.45
FGFR1 P11362 2/20 0.45
PLK4 O00444 2/20 0.45
ROCK2 O75116 2/20 0.45
PRKD3 O94806 2/20 0.45
MAP4K4 O95819 2/20 0.45
INSR P06213 2/20 0.45
CDK1 P06493 2/20 0.45
ROS1 P08922 2/20 0.45
FER P16591 2/20 0.45
CDK2 P24941 2/20 0.45
MARK3 P27448 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4831501 0.78 CDK8 (0.81) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL23655689 0.77 CDK8 (0.56) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL294106 0.75 CDK8 (0.55) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL3348675 0.75 CDK8 (0.55) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL926536 0.75 CDK8 (0.55) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL294108 0.75 CDK8 (0.55) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL12148007 0.75 CDK8 (0.55) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL297772 0.75 CDK8 (0.55) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL16774589 0.75 CDK8 (0.55) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL11968477 0.75 CDK8 (0.55) CDK8AXLPIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111217654-A Palladium-catalyzed meta-arylation reaction and application thereof in synthesis of vemurafenib analogue 陕西科技大学 2020-06-02 CN claimed
US-20250195516-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2025-06-19 US disclosed
CN-117304184-A Pyrrolo [2,3-b ] pyridine intermediate compound and preparation method and application thereof 南京羚诺生物医药技术研究院有限公司 2023-12-29 CN disclosed
US-20230391770-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LIMITED (GB) 2023-12-07 US disclosed
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2023-09-07 US disclosed
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2023-09-07 US disclosed
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2023-09-07 US disclosed
EP-4119560-A1 APOPTOSIS-INDUCING AGENTS Shanghai Fochon Pharmaceutical Co., Ltd. (CN) 2023-01-18 EP disclosed
US-20220220104-A1 PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) 2022-07-14 US disclosed
EP-3052501-B1 BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF AGENCY SCIENCE TECH & RES (SG) 2022-06-22 EP disclosed
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON, INC. 2010-11-11 US disclosed
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON, INC. 2010-11-11 US disclosed
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON, INC. 2010-11-11 US disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed
US-20100137280-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2010-06-03 US disclosed
WO-2009111278-A2 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2009-09-11 WO disclosed
WO-2008080015-A2 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2008-07-03 WO disclosed
WO-2008080001-A2 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2008-07-03 WO disclosed
WO-2008064255-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 WO disclosed
WO-2008063888-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391770-A1 METTL3 INHIBITORY COMPOUNDS METTL3, DIMT1, TPMT CDK8 1966/4885AXL 4180/4885PIK3CD 3819/4885
US-20100137280-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR HTR6, HTR4, HTR3C CDK8 4377/4885AXL 2526/4885PIK3CD 4489/4885
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, PRKACA, MAP3K13 CDK8 69/4885AXL 1476/4885PIK3CD 145/4885
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor BRAF, ARAF, RAF1 CDK8 136/4885AXL 97/4885PIK3CD 184/4885
US-20250195516-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, PRKACA, MAP3K13 CDK8 69/4885AXL 1476/4885PIK3CD 145/4885
US-20220220104-A1 PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF RET, BRAF, RAF1 CDK8 716/4885AXL 382/4885PIK3CD 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.